Terns Pharmaceuticals, Inc. (NASDAQ:TERN – Get Rating) major shareholder Vivo Opportunity, Llc purchased 600,000 shares of the company’s stock in a transaction that occurred on Wednesday, September 7th. The stock was acquired at an average cost of $3.60 per share, for a total transaction of $2,160,000.00. Following the transaction, the insider now owns 3,581,592 shares in the company, valued at approximately $12,893,731.20. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Major shareholders that own at least 10% of a company’s shares are required to disclose their sales and purchases with the SEC.
Vivo Opportunity, Llc also recently made the following trade(s):
- On Monday, August 15th, Vivo Opportunity, Llc purchased 1,218 shares of Terns Pharmaceuticals stock. The stock was acquired at an average cost of $2.99 per share, for a total transaction of $3,641.82.
- On Friday, August 12th, Vivo Opportunity, Llc acquired 1,123,021 shares of Terns Pharmaceuticals stock. The stock was purchased at an average price of $2.98 per share, with a total value of $3,346,602.58.
Terns Pharmaceuticals Stock Performance
NASDAQ:TERN opened at $5.27 on Friday. The firm has a market cap of $133.65 million, a price-to-earnings ratio of -2.47 and a beta of -0.33. Terns Pharmaceuticals, Inc. has a 52 week low of $1.45 and a 52 week high of $11.98. The firm has a 50-day moving average price of $3.12 and a two-hundred day moving average price of $2.61.
Institutional Investors Weigh In On Terns Pharmaceuticals
Several large investors have recently modified their holdings of TERN. Decheng Capital Management III Cayman LLC purchased a new stake in shares of Terns Pharmaceuticals during the 1st quarter worth approximately $2,121,000. Ikarian Capital LLC purchased a new stake in shares of Terns Pharmaceuticals during the 2nd quarter worth approximately $1,736,000. Affinity Asset Advisors LLC purchased a new stake in shares of Terns Pharmaceuticals during the 2nd quarter worth approximately $995,000. Point72 Asset Management L.P. increased its stake in shares of Terns Pharmaceuticals by 307.9% during the 2nd quarter. Point72 Asset Management L.P. now owns 500,000 shares of the company’s stock worth $1,240,000 after purchasing an additional 377,427 shares during the last quarter. Finally, Millennium Management LLC grew its stake in Terns Pharmaceuticals by 213.7% in the 2nd quarter. Millennium Management LLC now owns 277,688 shares of the company’s stock valued at $689,000 after buying an additional 189,178 shares in the last quarter. Hedge funds and other institutional investors own 92.50% of the company’s stock.
Terns Pharmaceuticals Company Profile
Terns Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops small-molecule single-agent and combination therapy candidates for the treatment of non-alcoholic steatohepatitis (NASH) and obesity. The company develops TERN-101, a liver-distributed and non-bile acid farnesoid X receptor agonist, which is in Phase IIa clinical trial for the treatment of NASH; and TERN-201, a vascular adhesion protein-1 inhibitor that is in Phase Ib clinical trial for the treatment of NASH.
- Get a free copy of the StockNews.com research report on Terns Pharmaceuticals (TERN)
- MarketBeat: Week in Review 9/5 – 9/9
- Prepare For A Record-Setting Quarter For Cyber Security Stocks
- The Auto Market Is Slowly Recovering, These Stocks May Outperform
- Is DocuSign On The Verge Of A Major Reversal?
- Oil and Gas Stocks: A Safe Way to Invest in Renewable Energy
Receive News & Ratings for Terns Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Terns Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.